Correction: Baseline Tumor Size Is an Independent Prognostic Factor for Overall Survival in Patients with Melanoma Treated with Pembrolizumab. uri icon

Overview

publication date

  • December 1, 2018

Identity

Scopus Document Identifier

  • 85057789854

Digital Object Identifier (DOI)

  • 10.1158/1078-0432.CCR-18-3340

PubMed ID

  • 30510087

Additional Document Info

volume

  • 24

issue

  • 23